Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279053 · ClinicalTrials.gov registry record
Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 58
- Enrollment target
NCT05279053: Completed study, sponsored by University of California, Los Angeles.
NCT05279053 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05279053 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 58 participants
- Enrollment target
Study Summary
The proposed study evaluated sex differences in glutamate (Glu), with a focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, as well as how it is influenced by sex (males vs. females), smoking state (overnight abstinent vs. sated), and circulating ovarian hormones (estrogen and progesterone) in women. Glu was measured in the entire brain with special focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, all of which have been implicated in tobacco withdrawal, using an echo-planar spectroscopic imaging (EPSI) variant of magnetic resonance spectroscopy (MRS). Serum ovarian hormones (estrogen and progesterone) were measured for female participants to determine relationships between brain Glu and this hormone. Glu was be measured in smokers after overnight (\~12 h) abstinence and after participants smoked the first cigarette of the day.
Primary Outcome
Glutamate levels, as measured using MRS, in the dorsal anterior cingulate cortex.
Interventions
- BEHAVIORAL Abstinence and Smoking
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2023-03-31 |
What the finished NCT05279053 record still lists
NCT05279053 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Abstinence and Smoking is the first listed.
NCT05279053 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05279053 about?
NCT05279053 is a clinical study titled "Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers". The proposed study evaluated sex differences in glutamate (Glu), with a focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, as well as how it is influenced by sex (males vs. females), smoking state (overnight abstinent vs. sated), and circulating ovarian hormones (es...
What is the current status of trial NCT05279053?
This trial is currently completed. The enrollment target is 58 participants. The study started on 2021-04-01. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT05279053?
The interventions under investigation include: Abstinence and Smoking (BEHAVIORAL).
Who is sponsoring clinical trial NCT05279053?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI